An observational study in Myocardial Infarction Type 2, sponsored by Uppsala University. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Uppsala University · Observational
A classic heart attack is caused by a blockage to the coronary arteries that supplies the heart muscle with oxygenated blood. The medical term for this condition is type 1 myocardial infarction. There is strong scientific evidence that the usage of pharmacological drugs such as statins, beta blockers, Renin-Angiotensin-Aldosterone System blockers and platelet inhibitors after a type 1 myocardial infarction improves survival and reduces the risk for new myocardial infarctions. However, a myocardial infarction may also occur without blockage to the coronary arteries when other acute conditions causes either a decreased supply or an increased demand of oxygenated blood to the heart. The medical term for the latter is type 2 myocardial infarction. There are currently no scientific evidence that any pharmacological drug improves survival in patients with a type 2 myocardial infarction, of whom only one in three patients are alive after five years.
The aim of this study is to investigate if those drugs that improves the prognosis after a type 1 myocardial infarction (Beta blockers, Renin-Angiotensin-Aldosterone System blockers, Statins and platelet inhibitors) also affects the prognosis after a type 2 myocardial infarction.
The best way to answer this question would be to conduct clinical trials for each drug where type 2 myocardial infarction patients are randomized to either receiving the drug of interest or receiving placebo (sugar pills) and then compare the survival and outcomes in both groups over time.
However, clinical trials are costly, time consuming and also difficult to conduct with type 2 myocardial infarction patients since these patients are treated at various hospital departments.
Therefore, this study will instead include patients in a Swedish national register for myocardial infarction, in which myocardial infarction patients are reported from all Swedish hospitals, and compare type 2 myocardial infarction patients that did receive or did not receive each treatment. To minimize the risk of making inaccurate conclusions about the causal relationship between treatment and outcome, the study will define the optimal clinical trial for each treatment and then specifically emulate these trials in all possible aspects using the register data. This method is called "target trial emulation".
While acute and long term treatments in type 1 myocardial infarction (MI) are well documented, there are no evidence based treatments altering the prognosis in type 2 MI patients, of whom only one in three are alive after five years. Classic secondary preventive treatment in type 1 MI include the use of statins, beta blockers, renin-angiotensin-aldosterone system (RAAS) inhibitors, single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT). While some observational studies suggest classic secondary preventive MI treatment to be associated with better survival in type 2 MI, others do not.
The aim of this study is to investigate if there is an association between treatment with each of statins, beta blockers, RAAS inhibitors, SAPT or DAPT; and all-cause mortality or long-term cardiovascular events in patients with type 2 MI.
The study will be conducted as (several) registry-based observational studies emulating pre-specified target trials. A protocol of a pragmatic randomized controlled trial (a target trial) will be specified for each of statins, beta blockers, RAAS inhibitors, SAPT and DAPT; including eligibility criteria, treatment assignment, time zero and follow up, outcomes, causal contrast and statistical analyses.
Each of these components will then be emulated using registry data. The target trial, as well as the registry-based study emulating the target trial, will differ slightly for each treatment.
The study will include all, approximately 14 000, patients reported as type 2 MI (first reporting for each patient) in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) from 2010 and onward. Data from SWEDEHEART will be merged with data from the National Patient Register, the Swedish Cause of Death Register and the Longitudinal Integrated Database for Health Insurance and Labour Market Studies.
Patients will be followed from hospital discharge (time zero) until death, loss to follow-up or end of follow up (date of data collection). Treatment specific eligibility criteria will be applied at time zero. All important confounding factors at time zero will be identified by drawing causal diagrams, one for each treatment and outcome. Treatment specific models with registry data will then be created to balance the assigned groups using for example inverse probability weighting with multiple imputation of missing data among covariates.
For all target trial emulations, the primary outcome of interest will be a composite endpoint of all-cause mortality, readmission for MI, stroke or heart failure. Secondary outcomes will be all-cause mortality, cardiovascular mortality, readmission for MI, readmission for stroke and readmission for heart failure individually. Safety outcomes will be specified separately for each treatment. Readmission for bacterial pneumonia will be used as a negative control outcome in all target trial emulations to check for residual confounding. Intention-to-treat analysis will be performed for each treatment and outcome. Competing risk methodology will be applied as appropriate.
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's enrollment of 14,000 is above the median of 500 across 983 observational studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →Uppsala University is the lead sponsor of 381 studies on the registry; 84 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients reported as type 2 myocardial infarction (first reporting) in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). SWEDEHEART is a Swedish national register for coronary artery disease care and valvular interventions. All Swedish hospitals report to SWEDEHEART. Reported myocardial infarction patients have been classified into type 1-5 since 2010 by the reporting physician. All patients will be included, from the first reporting, until the date of data collection.
Beta blocker target trial emulation:
Inclusion Criteria:
Exclusion Criteria:
RAAS blocker target trial emulation:
Inclusion Criteria:
Exclusion Criteria:
Statin target trial emulation:
Inclusion Criteria:
Exclusion Criteria:
Single Antiplatelet Therapy target trial emulation:
Inclusion Criteria:
Exclusion Criteria:
Dual Antiplatelet Therapy target trial emulation:
Inclusion Criteria:
Exclusion Criteria:
All patients reported as type 2 myocardial infarction (first reporting) in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)
Drug: Beta Blocker Therapy or No Therapy (Control) · Drug: RAAS blocker Therapy or No therapy (Control) · Drug: Statin Therapy or No Therapy (Control) · Drug: Single Antiplatelet Therapy or No Therapy (Control) · Drug: Dual Antiplatelet Therapy or No Therapy (Control)
Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction
RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction
Statin therapy or no Statin therapy initiated after type 2 myocardial infarction
Single Antiplatelet Therapy or no antiplatelet therapy initiated after type 2 myocardial infarction
Dual Antiplatelet Therapy or no Dual Antiplatelet Therapy initiated after type 2 myocardial infarction
Composite
Composite endpoint: All-cause mortality, readmission for MI, stroke or heart failure
Time frame: From enrollment (hospital discharge after type 2 MI) until Composite endpoint, Loss to follow-up or End of follow up (date of data collection: 05-May-2022)
All-cause mortality
Death from any cause
Time frame: From enrollment (hospital discharge after type 2 MI) until Death, Loss to follow-up or End of follow up (date of data collection: 05-May-2022)
Cardiovascular mortality
Death from cardiovascular disease
Time frame: From enrollment (hospital discharge after type 2 MI) until Cardiovascular death, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for MI
Readmission for myocardial infarction
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for MI, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for stroke
Readmission for stroke
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for Stroke, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for heart failure
Readmission for heart failure
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for Heart failure, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for Asthma or COPD
Safety outcome in Beta blocker target trial emulation. Readmission for Asthma or Chronic Obstructive Pulmonary Disease. Only if main diagnosis.
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for Asthma/COPD, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for Acute renal failure
Safety outcome in RAAS blocker target trial emulation. Readmission for Acute renal failure.
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for Acute renal failure, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for bleeding
Safety outcome in SAPT and DAPT target trial emulations. Readmission for bleeding.
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for Bleeding, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for Pneumonia
Negative control outcome in all target trial emulations. Readmission for bacterial pneumonia.
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for bacterial pneumonia, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Readmission for hip fracture
Additional negative control outcome in all target trial emulations. Readmission for hip fracture.
Time frame: From enrollment (hospital discharge after type 2 MI) until Readmission for hip fracture, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied.
Plan to share: Undecided — Due to Swedish laws on personal integrity and health data, as well as the Ethics Committee, we are not allowed to make any data included health variables open to the public even if made anonymous. The data could be shared with other researchers after a request to the head of our department
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Uppsala University